Coronavirus

New research using advanced MRI techniques explores how impaired pulmonary gas exchange may contribute to cognitive impairments in Long COVID patients, offering insights for potential treatment strategies.

New therapeutics offer some hope in this emerging market.

Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.

Clinicians discussed the complexities of diagnosing Long COVID, emphasizing the need for improved biomarkers and diagnostic technologies to better serve affected patients.

The CANOPY Phase 3 clinical trial demonstrated a reduced risk of symptomatic COVID-19, including a 64% reduction during the off-drug follow-up period.

Shionogi’s ensitrelvir demonstrated reduction of symptoms in phase 3 trial.

Important vaccine updates, including a second COVID-19 vaccine dose for adults 65 and older and immunocompromised individuals, a pneumococcal vaccine for adults aged 50 and older, and more.

Nigel McCracken, PhD, presents a diagnostic test to identify early T cell dysfunction in syndromes like Long COVID and ME/CFS, aiming to improve treatment strategies before symptoms escalate.

John McLaughlin, PhD, examines high-risk individuals with prior SARS-CoV-2 immunity and presents that Paxlovid reduces the risk of hospitalization, death, and severe symptoms, highlighting its ongoing value for high-risk patients in a post-peak pandemic landscape.

A NIH-funded study focused on analyzing the Wuhan strain in unvaccinated patients with COVID-19. Results showed those with certain blood types seemed to fare worse significantly increasing their risk for cardiovascular events and mortality.

Despite evidence of their effectiveness in reducing hospitalization and mortality rates, many older individuals remain untreated, with recent studies highlighting significant disparities in treatment access and adherence.

People can now take the Healgen Rapid Check COVID-19/Flu A&B Antigen Test in their homes without a prescription.

Part 2 with James F Cummings, MD, as he discusses the need for a stronger response to emerging variants, the importance of protecting high-risk populations, and the potential to reduce vaccine hesitancy through easier administration.

Part 1 of James F Cummings, MD interview, discusses the trial's goals and highlights the vaccine's potential to generate mucosal immunity, its logistical advantages and ease of administration.

A single dose of the mRNA-1273.222 vaccine demonstrated strong immune responses against various omicron subvariants and showed a favorable safety profile compared to existing vaccines.

Study finds this population saw a 45% reduction of ongoing symptoms in those with COVID-19 weeks later and who had received subsequent doses of the original monovalent vaccine.

The findings are from a National Foundation for Infectious Diseases (NFID) survey showing many Americans are not thinking about flu, COVID-19, RSV, or pneumococcal disease, and many respondents do not plan to get vaccinated this fall.

New research highlights a complex relationship between COVID-19 and cognitive function, suggesting that even mild infections can lead to subtle memory and attention deficits lasting at least a year.

Ammara Mushtaq, MD, discusses the underrepresentation of different races during the pandemic, but also the newer efforts to include and represent these communities in smaller, local studies.

The study estimates that vaccination efforts may have averted between 610,000 and 2.61 million deaths during the first 18 months of the rollout.

Katrine Wallace, PhD, and Eric John Burnett, MD, discuss the distinctions between them and strategies to understand better the information people are consuming.

Initially authorized based on promising trial data, recent analyses raise questions about the effectiveness of nirmatrelvir/ritonavir and molnupiravir against new viral variants, particularly regarding mortality and hospitalization rates.

A large study shows a moderate benefit to taking the antimalarial therapy.

Adults with type 2 diabetes who use metformin have a 13% to 21% reduced risk of developing Long COVID or dying from COVID-19 compared to those taking other diabetes medications.

The CSL and Arcturus Therapeutics’ vaccine, ARCT-154 (Kostaive), is designed to offer protection against the JN1 strain.

Ami Patel, PhD, provides insights on both technologies and how her research center, the Wistar Institute, is involved in DNA vaccine and monoclonal antibody research.

Females are more frequently affected by Long COVID than males, highlighting distinct immunological processes and hormonal variations.

Recent data and conversations with experts highlighted the increasing concern of Long COVID’s impact on the brain in patients who have been previously infected with the virus.

Syra Madad, DHSC, MSc, MCP, CHEP, outlines early surveillance systems and diagnostic innovations for enhancing pandemic management and response.

Atea pharmaceuticals' oral nucleotide RNA-dependent RNA polymerase inhibitor advances in phase 3 trials for COVID-19 and phase 2 trials for hepatitis C, showing potential efficacy.